New Millennium Group LLC Purchases Shares of 207,063 ADMA Biologics, Inc. (NASDAQ:ADMA)

New Millennium Group LLC purchased a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 207,063 shares of the biotechnology company’s stock, valued at approximately $4,139,000. ADMA Biologics comprises approximately 2.7% of New Millennium Group LLC’s investment portfolio, making the stock its 12th largest holding.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in ADMA Biologics during the second quarter valued at approximately $29,000. Hollencrest Capital Management acquired a new position in ADMA Biologics during the third quarter valued at approximately $30,000. EntryPoint Capital LLC acquired a new position in ADMA Biologics during the first quarter valued at approximately $31,000. CWM LLC grew its holdings in ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in ADMA Biologics during the second quarter valued at approximately $93,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Transactions at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. The trade was a 10.31 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 466,900 shares of company stock worth $8,224,121. 3.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright raised their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $19.25 on Tuesday. The stock has a 50-day simple moving average of $18.54 and a 200 day simple moving average of $14.45. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 12-month low of $3.60 and a 12-month high of $23.64. The stock has a market capitalization of $4.55 billion, a price-to-earnings ratio of 69.79 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the company earned $0.01 earnings per share. On average, research analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.